

---

# 5.90.008

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	December 4, 2015
<b>Subject:</b>	Zyclara	<b>Page:</b>	1 of 5

---

**Last Review Date:** December 13, 2024

---

## Zyclara

### Description

#### Zyclara (imiquimod)

---

#### Background

Zyclara (imiquimod) cream is used topically for actinic keratosis and external genital and perianal warts. Actinic keratosis (AK), also called solar keratosis, which is a chronic (long-term) condition of the skin caused by a chemical reaction to ultraviolet (UV) rays. Actinic keratosis can be linked to the development of skin cancer. External genital and perianal warts, also called condyloma acuminata (EGW), are caused by a virus known as human papillomavirus (HPV) and spread through sexual contact. Genital warts rarely cause health problems, but local symptoms of pain and itching may occur (1).

#### Regulatory Status

FDA-approved indications: Zyclara cream, 2.5% and 3.75% are indicated for the topical treatment of clinically typical, visible, or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults. Zyclara cream, 3.75% is also indicated for the topical treatment of external genital and perianal warts/condyloma acuminata (EGW) in patients 12 years and older (1).

#### Limitations of Use:

Efficacy of imiquimod cream was not demonstrated for molluscum contagiosum in children 2 to 12 years of age (1).

---

#### Related policies

Aldara, Klisyri, Solaraze

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	December 4, 2015
<b>Subject:</b>	Zyclara	<b>Page:</b>	2 of 5

---

## Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Zyclara may be considered **medically necessary** if the conditions indicated below are met.

Zyclara may be considered **investigational** for all other indications.

## Prior-Approval Requirements

### Diagnoses

Patient must have **ONE** the following:

1. Actinic keratosis (AK)
  - a. 18 years of age or older
  - b. **NOT** immunocompromised
  - c. Inadequate treatment response, intolerance, or contraindication to **TWO** of the following:
    - i. Generic imiquimod
    - ii. Fluorouracil
    - iii. Diclofenac
2. External genital and perianal warts (EGW)
  - a. 12 years of age or older
  - b. Inadequate treatment response, intolerance, or contraindication to **TWO** of the following:
    - i. Podofilox
    - ii. Generic imiquimod
    - iii. Cryotherapy

---

## Prior – Approval *Renewal* Requirements

### Diagnoses

Patient must have **ONE** the following:

1. Actinic keratosis (AK)
  - a. 18 years of age or older

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	December 4, 2015
<b>Subject:</b>	Zyclara	<b>Page:</b>	3 of 5

2. External genital and perianal warts (EGW)
  - a. 12 years of age or older

**AND ALL** of the following:

Re-evaluation of lesion(s) / warts for improvement

### Policy Guidelines

#### Pre - PA Allowance

None

#### Prior - Approval Limits

##### Quantity

##### Actinic keratosis (AK)

Zyclara 2.5% Pump	2 bottles <b>OR</b>
Zyclara 3.75% Pump	2 bottles <b>OR</b>
Zyclara 3.75% Packets	56 (2 boxes)

##### External genital and perianal warts (EGW)

Zyclara 3.75% Pump	2 bottles <b>OR</b>
Zyclara 3.75% Packets	56 (2 boxes)

**Duration** 3 months

#### Prior – Approval *Renewal* Limits

##### Quantity

##### Actinic keratosis (AK)

Zyclara 2.5% Pump	2 bottles <b>OR</b>
Zyclara 3.75% Pump	2 bottles <b>OR</b>
Zyclara 3.75% Packets	56 (2 boxes)

##### External genital and perianal warts (EGW)

Zyclara 3.75% Pump	2 bottles <b>OR</b>
Zyclara 3.75% Packets	56 (2 boxes)

**Duration** 3 months (One renewal only)

### Rationale

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	December 4, 2015
<b>Subject:</b>	Zyclara	<b>Page:</b>	4 of 5

---

### Summary

Zyclara (imiquimod) cream is a prescription medicine used topically for actinic keratosis and external genital and perianal warts. Actinic keratosis (AK) is a chronic (long-term) condition of the skin and can be linked to the development of skin cancer. External genital and perianal warts, also called condyloma acuminata (EGW), are caused by a virus known as human papillomavirus (HPV) and spread through sexual contact. Genital warts rarely cause health problems, but local symptoms of pain and itching may occur. Efficacy of imiquimod cream was not demonstrated for molluscum contagiosum in children 2 to 12 years of age (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Zyclara while maintaining optimal therapeutic outcomes.

### References

1. Zyclara [package Insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC.; February 2018.

### Policy History

Date	Action
December 2015	Addition to PA
March 2016	Annual review Policy number changed from 5.14.08 to 5.90.08
December 2016	Annual editorial review Addition of not immunocompromised in AK and dosing limits (3.75% only) for EGW
September 2017	Annual editorial review and reference update
September 2018	Annual review and reference update
September 2019	Annual review and reference update
September 2020	Annual review
March 2021	Annual editorial review
December 2022	Annual review. Changed policy number to 5.90.008
September 2023	Annual review
June 2024	Annual review. Per SME, changed step requirement for trichloroacetic acid to cryotherapy and fluorouracil to generic imiquimod
September 2024	Annual review
December 2024	Annual review

### Keywords

---

# 5.90.008

---

**Section:** Prescription Drugs

**Effective Date:** January 1, 2025

**Subsection:** Topical Products

**Original Policy Date:** December 4, 2015

**Subject:** Zyclara

**Page:** 5 of 5

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 13, 2024 and is effective on January 1, 2025.**